Marshall Wace North America’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Marshall Wace North America’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-843,451	Closed	-$9.28M	–	1798
2017 Q3	$9.28M	Buy	843,451 +600,767	+248%	+$6.63M	0.06%	382
2017 Q2	$2.67M	Buy	242,684 +223,144	+1,142%	+$2.23M	0.02%	665
2017 Q1	$195K	Buy	+19,540	New	+$195K	﹤0.01%	918

Marshall Wace North America's SCLN Position: Q4 2017 in Review

Marshall Wace North America sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 843,451 shares — an estimated $9.28M sold.

Marshall Wace North America first reported a position in SCLN in Q1 2017 and held it in 3 quarters. The position peaked at $9.28M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Marshall Wace North America reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Marshall Wace North America sold 843,451 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $9.28M.
Marshall Wace North America first reported a position in Sciclone Pharmaceuticals Inc in Q1 2017 and held it in 3 quarters.
Marshall Wace North America's Sciclone Pharmaceuticals Inc position peaked at $9.28M in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.